CEBPZ and acute myeloid leukemia: Normalized mtDNAc levels (using a healthy control reference sample included in all experiments) ranged from 0.05 to 21.4 in AML samples and 0.1 to 2.45 in healthy volunteers, indicating that mtDNAc is significantly higher in AML patients, particularly those with normal karyotypes (NK), core binding factor (CBF), and not otherwise specified (NOS) AML (Fig. 1a).